cael-101
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Aug 25, 2020 (NCT04512235)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04504825 | Phase 3 | Aug 25, 2020 | Fortress Biotech, IQVIA |
| NCT04512235 | Phase 3 | Aug 25, 2020 | Fortress Biotech, IQVIA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fortress Biotech | For profit | 2 | 2 | 1 | 2020 |
| IQVIA | For profit | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1